2012-10-10 21:37:50 - New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research

Global Market Direct's pharmaceuticals report, "Mayne Pharma Limited - Product Pipeline Review - 2012" provides data on the Mayne Pharma Limited's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Mayne Pharma Limited's corporate website, SEC filings, investor presentations and featured press releases, both from Mayne Pharma Limited and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

* Mayne Pharma Limited - Brief Mayne Pharma Limited overview including business description, key information and facts, and its locations and subsidiaries.
* Review of current pipeline of Mayne Pharma Limited human

therapeutic division.
* Overview of pipeline therapeutics across various therapy areas.
* Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
* Product profiles for late stage and clinical stage products of Mayne Pharma Limited with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
* Recent updates of the Mayne Pharma Limited's pipeline in the last quarter.
* Key discontinued and dormant projects.
* Latest news and deals relating to the products.


Full Report Details at
- www.fastmr.com/prod/468558_mayne_pharma_limited_product_pipeline ..


Reasons to buy

* Evaluate Mayne Pharma Limited's strategic position with total access to detailed information on its product pipeline.
* Assess the growth potential of Mayne Pharma Limited in its therapy areas of focus.
* Identify new drug targets and therapeutic classes in the Mayne Pharma Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
* Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
* Exploit collaboration and partnership opportunities with Mayne Pharma Limited.
* Avoid Intellectual Property Rights related issues.
* Explore the dormant and discontinued projects of Mayne Pharma Limited and identify potential opportunities in those areas.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Mayne Pharma Limited Snapshot
Mayne Pharma Limited Overview
Key Information
Key Facts
Mayne Pharma Limited - Research and Development Overview
Key Therapeutic Areas
Mayne Pharma Limited - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Mayne Pharma Limited - Pipeline Products Glance
Mayne Pharma Limited - Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Mayne Pharma Limited Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Mayne Pharma Limited - Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Mayne Pharma Limited - Drug Profiles
cimetidine
Product Description
Mechanism of Action
R&D Progress
diclofenac Sustained Release
Product Description
Mechanism of Action
R&D Progress
diltiazem hydrochloride
Product Description
Mechanism of Action
R&D Progress
fluoxetine
Product Description
Mechanism of Action
R&D Progress
hydrocodone bitartrate
Product Description
Mechanism of Action
R&D Progress
itraconazole
Product Description
Mechanism of Action
R&D Progress
minocycline
Product Description
Mechanism of Action
R&D Progress
nifedipine
Product Description
Mechanism of Action
R&D Progress
oxycodone
Product Description
Mechanism of Action
R&D Progress
Pseudoephidrine
Product Description
Mechanism of Action
R&D Progress
risperidone
Product Description
Mechanism of Action
R&D Progress
theophylline
Product Description
Mechanism of Action
R&D Progress
zolpidem
Product Description
Mechanism of Action
R&D Progress
Mayne Pharma Limited - Pipeline Analysis
Mayne Pharma Limited - Pipeline Products by Therapeutic Class
Mayne Pharma Limited - Pipeline Products by Route of Administration
Mayne Pharma Limited - Pipeline Products By Mechanism of Action
Mayne Pharma Limited - Recent Pipeline Updates
Mayne Pharma Limited - Dormant Projects
Mayne Pharma Limited - Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Mayne Pharma Limited, Key Information
Mayne Pharma Limited, Key Facts
Mayne Pharma Limited - Pipeline by Indication, 2012
Mayne Pharma Limited - Pipeline by Stage of Development, 2012
Mayne Pharma Limited - Monotherapy Products in Pipeline, 2012
Mayne Pharma Limited - Filed, 2012
Mayne Pharma Limited - Phase II, 2012
Mayne Pharma Limited - Phase I, 2012
Mayne Pharma Limited - Pre-Clinical, 2012
Mayne Pharma Limited - Pipeline By Therapeutic Class, 2012
Mayne Pharma Limited - Pipeline By Route of Administration, 2012
Mayne Pharma Limited - Pipeline Products By Mechanism of Action, 2012
Mayne Pharma Limited - Recent Pipeline Updates, 2012
Mayne Pharma Limited - Dormant Developmental Projects,2012

List of Figures

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=468558&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.